STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling

Withdrawn before enrolling · Phase 2

Conditions studied: Adenocarcinoma of the Prostate

In brief

In this research study, the investigators are looking to determine the safety and efficacy of an investigational drug, STA9090 alone and in combination with dutasteride for the treatment of castrate resistant prostate cancer. STA9090 may cause the growth of cancer to slow down or shrink by targeting proteins required for the cancer to grow. The investigators are also looking to determine whether the use of dutasteride to lower male hormone levels will enhance the effect of STA9090 in the treatment of castrate resistant prostate cancer.

Key facts

Study ID: NCT01368003
Run by: Toni Choueiri, MD
People needed: 0
Starts: 2011-04-01
Expected to finish: 2012-11-01
Last updated by the study team: 2015-09-01

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

Adenocarcinoma of the prostate
Progressive castration resistant disease
Metastatic disease
Normal organ and marrow function

You may not qualify if…

History of current coronary artery disease, myocardial infarction, angina pectoris, angioplasty or coronary bypass
Current treatment with the following antiarrhythmic drugs: flecainide, moricizine or propafenone
New York Heart Association class II/III/IV congestive heart failure
Current or prior radiation therapy to the left hemithorax
Treatment with chronic immunosuppressants
Uncontrolled intercurrent illness
Poor venous access for study drug administration
Venous thromboembolism in the past 6 months

Where it is running

Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
Dana-Farber Cancer Institute — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.